Follow-The-Filings

Security · featured owners

XENE Xenon Pharmaceuticals Inc.

COM Equity as of 2026 Q2 among managers we track

  • 4 Owners
  • Max 2.9%
  • $34M

Who owns this now

Largest portfolio weights among featured holders · max 2.9% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel 2.9%
  2. Palo Alto Investors 0.43%
  3. Stanley Druckenmiller 0.28%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 2.9% Hold 250,772 $15M history
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.28% Hold 238,600 $14M history
Palo Alto Investors 2026 Q2 0.43% Hold 51,345 $3M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Hold 25,000 $2M history

4 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Net income -$182.39M -$234.33M -$345.91M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $644.96M $635.26M $560.65M
Total non-current assets * $319.84M $162.88M $72.51M
Total assets $964.8M $798.14M $633.16M
Total current liabilities $27.27M $35.59M $41.79M
Total non-current liabilities * $9.6M $7.65M $9.61M
Total equity $927.92M $754.9M $581.76M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$145.33M -$181.39M -$279.12M
Cash from investing -$117.17M $165M $218M
Cash from financing $353.52M $12.13M $117.11M
Net change in cash $91.4M -$5.93M $56.45M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders